(Total Views: 955)
Posted On: 06/27/2020 2:13:41 PM
Post# of 154053
Regarding my post from last night about the ~100M options granted to the 4 board of directors.
We know the 51st patient in the P3 S/C trial was injected at the end of May. I personally believe it was during the last week of May -- and not on May 31.
However, even in a worst case scenario (injection on May 31), the Day 28 Mortality endpoint will be reached tomorrow – June 28. As mentioned above, I think the last patient’s Day 28 endpoint was actually reached earlier this week.
My point is, CytoDyn would not have granted options to their most trusted and loyal Directors at a strike price of $6.15 (Thursday’s closing price) if they thought the top-line readout would likely result in an erosion of the stock price.
There would be absolutely no reason to do that.
Does that mean that CytoDyn definitively *knows* that they will be granted at least one FDA approval for COVID – probably not.
However, I submit that granting those option quantities, at a strike price of $6.15, and at this specific moment in time -- is a high conviction “tell” that the company anticipates favorable stock price trends.
And more importantly, it strongly suggests that the company believes there is a low probability that the stock price is going to drop below that strike price.
We know the 51st patient in the P3 S/C trial was injected at the end of May. I personally believe it was during the last week of May -- and not on May 31.
However, even in a worst case scenario (injection on May 31), the Day 28 Mortality endpoint will be reached tomorrow – June 28. As mentioned above, I think the last patient’s Day 28 endpoint was actually reached earlier this week.
My point is, CytoDyn would not have granted options to their most trusted and loyal Directors at a strike price of $6.15 (Thursday’s closing price) if they thought the top-line readout would likely result in an erosion of the stock price.
There would be absolutely no reason to do that.
Does that mean that CytoDyn definitively *knows* that they will be granted at least one FDA approval for COVID – probably not.
However, I submit that granting those option quantities, at a strike price of $6.15, and at this specific moment in time -- is a high conviction “tell” that the company anticipates favorable stock price trends.
And more importantly, it strongly suggests that the company believes there is a low probability that the stock price is going to drop below that strike price.
(6)
(1)
